Careers at Amgen
A panel discussion in partnership with iJOBS
September 21st 2023
We Serve Patients Suffering from Serious Illness
Our Products Reflect Our Commitment
To Serving Patients Living With Serious Illness

27 FDA-approved products on the market for a variety of indications spanning
Oncology, inflammation, bone health, neuroscience, nephrology and cardiovascular disease
We serve millions of seriously ill patients living with cancer, inflammatory diseases, cardiovascular disease and more.
FOUNDED
1980

GLOBAL HQ
Thousand Oaks, California, USA

EMPLOYEES
25,000+

# OF PATIENTS REACHED
~10 million
ANNUALLY

R&D INVESTMENT
$4.4 billion
IN 2022

DONATIONS
$2.2 billion*
Through AMGEN SAFETY NET FOUNDATION IN 2022

MARKETS
~100

TOTAL REVENUE
$26.3 billion
IN 2022

*Valued at wholesale acquisition cost.
Organizational structure

- Research and Development
- Operations
- Global Commercial Operations

- Business Development
- Finance
- Human Resources
- Corporate Affairs
- Information Systems
- Legal
- Medical Affairs
Geographical footprint: Amgen R&D/Operations/BD

Global research and manufacturing sites:
- Burnaby (British Columbia, Canada)
- Copenhagen (Denmark)
- Reykjavik (Iceland)
- Dun Laoghaire (Ireland)
- Singapore
Panelist introductions

Andrew Holland, PhD
Director, Precision Oncology

Ngoni Madungwe, PhD
Senior Scientist, Process Development

Bhargava Nemmaru, PhD
Senior Scientist, Process Development
(Co-Moderator)

Juma Bridgewater, PhD
Associate Director, Process Development

Duncan Huston-Paterson, PhD
Director, Business Development
I am in the Precision Oncology Therapeutic Area. Our goal is to identify and validate targets that cancer cells rely on for proliferation and design small molecule therapeutics to interdict these targets.

I was raised and educated in the UK. I moved to the US in 2007 for a postdoctoral fellowship and joined the faculty at Johns Hopkins University School of Medicine in 2013. I joined Amgen in February of this year.

**Education:**
PhD, University of Manchester (2006)

**Employment:**
Postdoc, UCSD (2007 – 2013)
Asst Professor – Professor, Johns Hopkins University (2013 – 2023)
Amgen (2023 – Present)
Ngoni Madungwe, PhD
Senior Scientist, Process Development

I am in the Pivotal Biologics Drug Substance group (sub-group in Process Development) focused on upstream cell culture process design and characterization to enable process transfer from lab scale to pilot plant and commercial scale for cell-derived protein therapies.

**Education:**
PhD, UT Health San Antonio (2020)

**Employment:**
Amgen (2020 – Present)
Juma Bridgewater, PhD
Associate Director, Process Development

I am a scientist in the attribute sciences group. We support the process development of products in the clinic with testing methods that ensure product quality. We also fully characterize our molecules to understand which molecular features need to be controlled during processing and storage.

Education:
PhD, Umass Amherst (2006)

Employment:
Abbott (2008 – 2011)
Immunogen (2011 – 2015)
BMS (2015 – 2021)
Amgen (2021 – Present)
Duncan Huston-Paterson, PhD
Director, Business Development

I am part of the Business Development team focused on technologies to enable the next generation of Amgen drugs.

My team identifies innovative technologies and platforms, and then negotiates the business deals to bring them into Amgen.

**Education:**
PhD, University of Oxford (2015)

**Employment:**
Integral Molecular (2015 – 2019)
Amgen (2019 – Present)
Bhargava Nemmaru, PhD
Senior Scientist, Process Development

I am in the Pivotal Biologics Drug Substance group (sub-group in Process Development) focused on downstream process design and characterization to enable process transfer from lab scale to pilot plant and commercial scale for protein therapeutics.

Education:
PhD, Rutgers University (2021)

Employment:
Amgen (2021 – Present)